KR20250009454A - 릴랙신 또는 유사체의 융합 단백질 및 이의 의약적 용도 - Google Patents

릴랙신 또는 유사체의 융합 단백질 및 이의 의약적 용도 Download PDF

Info

Publication number
KR20250009454A
KR20250009454A KR1020247039736A KR20247039736A KR20250009454A KR 20250009454 A KR20250009454 A KR 20250009454A KR 1020247039736 A KR1020247039736 A KR 1020247039736A KR 20247039736 A KR20247039736 A KR 20247039736A KR 20250009454 A KR20250009454 A KR 20250009454A
Authority
KR
South Korea
Prior art keywords
seq
serum albumin
amino acid
chain
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039736A
Other languages
English (en)
Korean (ko)
Inventor
얀핑 두
레이 왕
시아오 리우
홍 가오
천시 선
린슈앙 장
펑 지앙
Original Assignee
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 filed Critical 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드
Publication of KR20250009454A publication Critical patent/KR20250009454A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020247039736A 2022-05-07 2023-05-05 릴랙신 또는 유사체의 융합 단백질 및 이의 의약적 용도 Pending KR20250009454A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210491720.7 2022-05-07
CN202210491720 2022-05-07
PCT/CN2023/092214 WO2023216981A1 (zh) 2022-05-07 2023-05-05 松弛素或类似物的融合蛋白及其医药用途

Publications (1)

Publication Number Publication Date
KR20250009454A true KR20250009454A (ko) 2025-01-17

Family

ID=88729678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247039736A Pending KR20250009454A (ko) 2022-05-07 2023-05-05 릴랙신 또는 유사체의 융합 단백질 및 이의 의약적 용도

Country Status (10)

Country Link
US (1) US20250312444A1 (cg-RX-API-DMAC7.html)
EP (1) EP4524156A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025517100A (cg-RX-API-DMAC7.html)
KR (1) KR20250009454A (cg-RX-API-DMAC7.html)
CN (1) CN119032105A (cg-RX-API-DMAC7.html)
AU (1) AU2023266749A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252059A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013712A (cg-RX-API-DMAC7.html)
TW (1) TW202409074A (cg-RX-API-DMAC7.html)
WO (1) WO2023216981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN122122198A (zh) * 2023-11-08 2026-05-29 北京拓界生物医药科技有限公司 融合蛋白及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2766160A1 (en) * 2000-12-12 2002-08-08 William Dall'acqua Modified molecules with increased affinity for fcrn, compositions, and uses thereof
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AU2012283235A1 (en) * 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
KR20160071472A (ko) 2013-11-07 2016-06-21 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 릴렉신 유사체, 이의 약제학적 조성물 및 이의 약제학적 적용
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN112409480B (zh) * 2019-08-20 2024-08-27 四川科伦博泰生物医药股份有限公司 结合血清白蛋白的蛋白及其用途
CN112851805B (zh) * 2019-11-12 2025-09-09 四川科伦博泰生物医药股份有限公司 一种结合血清白蛋白的蛋白及其用途
CR20230015A (es) 2020-06-17 2023-02-17 Medimmune Ltd Fusiones heterodiméricas de relaxina y usos de las mismas

Also Published As

Publication number Publication date
JP2025517100A (ja) 2025-06-03
CN119032105A (zh) 2024-11-26
MX2024013712A (es) 2024-12-06
CA3252059A1 (en) 2025-07-07
TW202409074A (zh) 2024-03-01
US20250312444A1 (en) 2025-10-09
AU2023266749A1 (en) 2024-11-07
WO2023216981A1 (zh) 2023-11-16
EP4524156A4 (en) 2025-10-22
EP4524156A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
JP7444886B2 (ja) 補体関連疾患のための融合タンパク質構築物
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
KR20220086554A (ko) Her3 항원-결합 분자를 사용한 암의 치료 및 예방
US20220185875A1 (en) Bispecific antibody specifically bound to vegf and ang2
US20250312444A1 (en) Fusion protein of relaxin or analogue and medical use thereof
TW200944234A (en) Humanized anti-Factor D antibodies and uses thereof
MX2014009864A (es) Polipeptidos de union a cx3cr1.
TWI815136B (zh) 一種雙特異性抗體及其用途
JP2022505604A (ja) 抗npr1抗体およびその使用
CN115109156A (zh) 一种靶向bcma的纳米抗体及其应用
CN118240082A (zh) Pd-1结合分子及其应用
US12630616B2 (en) Complement C2 binding proteins and uses thereof
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
CN112996811B (zh) 双特异性蛋白
WO2024094076A1 (zh) 一种gipr结合蛋白及其应用
KR20230035079A (ko) 응고인자 xi(fxi) 결합 단백질
EP4613767A1 (en) Bispecific antibody for glypican-3 and use thereof
WO2025098472A1 (zh) 融合蛋白及其医药用途
RU2784486C1 (ru) Биспецифический белок
US20250154242A1 (en) Anti-tnf-alpha antibodies and compositions
HK40051451A (en) Bispecific protein
HK40051458A (en) Bispecific antibody specifically bound to vegf and ang2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241128

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application